GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines
GSK and the biopharmaceutical firm Curevac have agreed to restructure their existing partnership in a €1.45bn (£1.2bn) deal that will see the former acquire rights to manufacture and commercialise vaccines…